Dana-Farber Cancer Institute
Boston, MA
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
CA088-1005
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 1
- Has results
Accepting patients
CA057-003
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- CELMoD
- Phase 1/2
- Has results
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- CD3
- BCMA
- Phase 2
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- BCMA
- CD3
- Phase 1
- Has results
Accepting patients
ISABELA
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)
- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- H3K36me2
- Phase 1
- Has results
Accepting patients
Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Monoclonal Antibody
- SLAMF7
- Phase 1/2
5 hidden based on your filters.Show All